利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

80 条记录 (耗时 0.046 秒)

    Osmotic device comprising means for governing initial time of agent release therefrom
    66.
    发明授权
    Osmotic device comprising means for governing initial time of agent release therefrom 失效
    渗透装置包括用于控制药剂从其释放的初始时间的装置

    公开(公告)号：US4609374A

    公开(公告)日：1986-09-02

    申请号：US725961

    申请日：1985-04-22

    申请人： Atul D. Ayer

    发明人： Atul D. Ayer

    IPC分类号： A61K9/00 ,  A61K9/22 ,  A61K9/36 ,  A61K9/62

    CPC分类号： A61K9/0004

    摘要： An osmotic dispensing device is disclosed for delivering a medicine to a biological environment of use. The device comprises a semipermeable wall surrounding a compartment with an osmotic passageway in the semipermeable wall connecting the outside of the device with the compartment. The compartment house a medicine releasably held on a carrier member selected from the group consisting of cellulose esters, cellulose ethers and cellulose ester-ethers.

    摘要翻译： 公开了用于将药物递送到生物生物学环境的渗透分配装置。 该装置包括围绕隔室的半透壁，该隔室具有连接设备外部与隔室的半透壁中的渗透通道。 隔室装有一种可释放地保持在选自纤维素酯，纤维素醚和纤维素酯 - 醚的载体上的药物。

    CONTROLLED RELEASE FORMULATIONS OF OPIOID AND NONOPIOID ANALGESICS
    70.
    发明申请
    CONTROLLED RELEASE FORMULATIONS OF OPIOID AND NONOPIOID ANALGESICS 审中-公开
    阿片类和非诺贝特药物的控制释放配方

    公开(公告)号：US20100221293A1

    公开(公告)日：2010-09-02

    申请号：US12716086

    申请日：2010-03-02

    申请人： Evangeline Cruz ,  Atul D. Ayer ,  Brenda J. Pollock ,  Carmelita Garcia ,  Sherry Li ,  Alfredo M. Wong ,  Lawrence G. Hamel ,  Cheri Enders Klein ,  Yihong Qiu ,  Ye Huang

    发明人： Evangeline Cruz ,  Atul D. Ayer ,  Brenda J. Pollock ,  Carmelita Garcia ,  Sherry Li ,  Alfredo M. Wong ,  Lawrence G. Hamel ,  Cheri Enders Klein ,  Yihong Qiu ,  Ye Huang

    IPC分类号： A61K31/485 ,  A61K9/00 ,  A61P25/00

    CPC分类号： A61K9/2086 ,  A61K9/0004 ,  A61K9/209 ,  A61K9/4808 ,  A61K9/5084 ,  A61K31/00 ,  A61K31/16 ,  A61K31/165 ,  A61K31/167 ,  A61K31/485 ,  A61K45/06 ,  A61K2300/00

    摘要： Sustained release dosage forms for twice daily oral dosing to a human patient for providing relief from pain are provided. The sustained release dosage form comprises an immediate release component and a sustained release component, wherein the immediate release component and the sustained release component collectively contain a therapeutically effective amount of an opioid analgesic and a therapeutically effective amount of nonopioid analgesic. In a preferred embodiment, the nonopioid analgesic is acetaminophen and the opioid analgesic is hydrocodone and pharmaceutically acceptable salts thereof, and in preferred embodiments, the pharmaceutically acceptable salt is bitartrate. The dosage forms produce plasma profiles in a patient characterized by a Cmax for hydrocodone of between about 0.6 ng/mL/mg to about 1.4 ng/mL/mg and an AUC for hydrocodone of between about 9.1 ng*hr/mL/mg to about 19.9 ng*hr/mL/mg (per mg hydrocodone bitartrate administered) and a Cmax for acetaminophen of between about 2.8 ng/mL/mg and 7.9 ng/mL/mg and an AUC for acetaminophen of between about 28.6 ng*hr/mL/mg and about 59.1 ng*hr/mL/mg (per mg acetaminophen administered) after a single dose.

    摘要翻译： 提供了持续释放剂型，每天两次口服给予患者以缓解疼痛。 持续释放剂型包括速释组分和持续释放组分，其中速释组分和持续释放组分共同含有治疗有效量的阿片样镇痛剂和治疗有效量的非阿片类止痛剂。 在优选的实施方案中，非阿片类镇痛剂是对乙酰氨基酚，阿片类镇痛剂是氢可酮及其药学上可接受的盐，并且在优选的实施方案中，药学上可接受的盐是酒石酸氢盐。 剂型在患者中产生血浆曲线，其特征在于氢可酮的C max为约0.6ng / mL / mg至约1.4ng / mL / mg，氢可酮的AUC为约9.1ng * hr / mL / mg至约 19.9ng * hr / mL / mg（每毫克给予的氢可酮酮可乐酮），对乙酰氨基酚的C max为约2.8ng / mL / mg至7.9ng / mL / mg，对乙酰氨基酚的AUC为约28.6ng * hr / mL / mg和约59.1ng * hr / mL / mg（施用每mg对乙酰氨基酚）。